HTR1A and cutaneous mastocytosis: Our results suggest that the therapeutic effect of WZYD on CM may be associated with 5-HT and 5-HT1A/3A receptors, as it reversed the decreased expression of 5-HT1A receptors and the increased expression of 5-HT3A receptors in the brain and colon of CM rats.